By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is overwhelmingly bearish on PFE, GIS, and UPS, citing structural headwinds, patent cliffs, and unsustainable dividend yields. They agree that these companies are not value investments but potential value traps.
Risk: Dividend cuts due to unsustainable payout ratios and earnings disappointments
Opportunity: Potential re-rating due to interest rate sensitivity (Gemini's stance)
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Pfizer has a long and successful history of developing new and profitable drugs.
General Mills focuses on industry-leading brands and has often adjusted its portfolio to keep pace with consumer tastes.
United Parcel Service has a strong brand and distribution network to support its turnaround effort.
Investors tend to move in groups, like lemmings. Sometimes that pushes stocks to unsustainable heights. Other times, it leaves good companies with deeply unloved stocks.
Bubbles are a huge risk, but down-and-out stocks can be a huge opportunity for long-term investors if you do your research. That's why you should dig into Pfizer (NYSE: PFE), General Mills (NYSE: GIS), and United Parcel Service (NYSE: UPS) today. Here's why each one could be due for a major rebound.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Pfizer's stock is down roughly 50% from its 2021 high. That peak was partly driven by the company's COVID vaccine, as investors overestimated long-term demand. However, the company is facing other headwinds, as well. For example, it has fallen behind in the GLP-1 weight-loss space, and the drugmaker has several patent expirations coming up.
There are reasons to be worried. However, with a $150 billion market cap, Pfizer remains a large and well-respected pharmaceutical giant. It continues to work on GLP-1 candidates, and it has oncology and migraine drugs in the works, as well. The big issue is really that patent expirations happen on a pre-set timeline, but drug discovery and development do not. Nothing Pfizer is dealing with is abnormal, and given enough time, it is likely to come through this difficult period. When it does, the stock should rebound, rewarding investors willing to think long term.
General Mills' stock is down 60% from its 2023 high. The downturn has been driven by several concerns. Inflation has put pressure on the food maker's margins, weight-loss drugs have changed consumer buying preferences, and economic concerns have led to tighter food budgets. General Mills entered fiscal 2026 warning that it would be an investment year. It has been, noting that organic sales were down 3% through the first three quarters of the year.
In the short-term, General Mills is doing poorly. However, it isn't unusual for a food company to have to rework its brand portfolio to better align with current consumer trends. It takes a little time, but good companies get back on track. General Mills has long focused on owning industry-leading brands and can stand up to any peer in distribution, marketing, and advertising. With an over 125-year history, it is highly likely that the company's investment year leads to improved results in the future. Buying while the stock is unloved could get you in before a major rebound.
United Parcel Service's stock has fallen more than 50% from its 2022 high. That high was partly driven by the COVID pandemic and the resulting increase in shipping due to social distancing. When the world reopened, shipping declined, and UPS embarked on a business overhaul. The goal has been to cut costs, refocus on its most profitable customers, and upgrade the company's infrastructure. From a big-picture perspective, costs rose, at least temporarily, while revenues were falling. The company's earnings reports have been pretty dismal to read.
However, there are early signs of success, as the revenue per piece in the United States has been moving higher despite falling overall revenues. That's basically the goal, as UPS attempts to become a more profitable company that is less reliant on high volume, but low profit margin, customers. The industrial company believes the second half of 2026 will be the inflection point, so buying now while Wall Street is still deeply negative could get investors in before the big business rebound starts.
The chance to get in early on some rebounding stocks is nice, but that's not the only story here. Pfizer's dividend yield is an attractive 6.5%, General Mills' yield is 7%, and UPS' is 6.6%. So you will be well paid while you wait for these turnaround stories to play out.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $473,985! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,204,650!
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 6, 2026. *
Reuben Gregg Brewer has positions in General Mills. The Motley Fool has positions in and recommends Pfizer and United Parcel Service. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"High dividend yields in these specific firms currently act as 'yield traps' masking structural revenue stagnation and margin compression rather than representing genuine value opportunities."
This article relies on a 'mean reversion' fallacy, assuming that because PFE, GIS, and UPS are down 50-60% from peaks, they are inherently undervalued. This ignores structural degradation. PFE faces a 'patent cliff' where $17 billion in revenue is at risk by 2030, likely necessitating dilutive M&A. GIS is battling a permanent shift in consumer demand driven by GLP-1 adoption, which isn't just an 'investment year' issue but a secular headwind. UPS is struggling with labor cost inflation from the Teamsters contract, which structurally compresses margins regardless of 'right-sizing.' Investors are being lured by high dividend yields that may become unsustainable if free cash flow fails to cover payout ratios in a high-interest environment.
If these companies successfully deleverage and execute cost-cutting, their current depressed valuations could offer a massive margin of safety for patient income-focused investors.
"High yields mask dividend sustainability risks amid patent cliffs, GLP-1 disruptions, and e-commerce slowdowns that history won't automatically reverse."
This Motley Fool piece pushes a classic value trap narrative on PFE, GIS, and UPS, citing history, high yields (6.5-7%), and 'inevitable' turnarounds, but glosses over structural shifts. PFE's patent cliffs loom without GLP-1 breakthroughs, risking prolonged revenue erosion beyond COVID fade. GIS faces secular pressure from GLP-1 drugs curbing processed food demand, with organic sales already -3% in FY2026 Q1-Q3. UPS's volume drops post-COVID persist, and revenue-per-piece gains may not offset Amazon's logistics encroachment. Yields look juicy but signal dividend cut risks if earnings disappoint further—patience alone won't deliver rebounds amid execution uncertainties.
If PFE's oncology/migraine pipeline hits, GIS realigns brands successfully post-investment year, and UPS nails its H2 2026 profitability inflection, these could rerate sharply from depressed multiples with yields paying handsomely in the interim.
"High yields on fallen stocks often signal permanent margin compression, not temporary undervaluation—and this article provides zero quantitative evidence (DCF, peer multiples, cash flow recovery timeline) that these three will rebound rather than slowly decay."
This article conflates 'unloved' with 'undervalued'—a dangerous leap. PFE faces real patent cliffs (Lipitor, Lyrica exclusivity ending 2024-2026); GLP-1 headwinds aren't temporary noise but structural demand destruction in legacy categories; GIS organic sales down 3% YTD suggests portfolio rework is failing, not pending success. UPS's 'revenue per piece' metric obscures that absolute volumes are contracting faster than margin expansion can offset. The 6.5-7% yields look attractive until you realize they're pricing in stagnation, not rebound. Article offers no timeline, no catalysts, no margin-of-safety math—just 'good companies get back on track eventually.'
If GLP-1 adoption plateaus and consumer preferences revert, GIS's portfolio shift could prove prescient; UPS's cost discipline might deliver 2H26 inflection as claimed; Pfizer's oncology pipeline (Daurismo, Velsipity) could offset patent losses faster than consensus expects.
"Catalysts are uncertain and the risk-reward favors patience until earnings momentum confirms durable improvement in pipelines, margins, and demand."
Here's the catch: the article cherry-picks optimism on PFE, GIS, and UPS and nudges readers toward a rebound narrative. Pfizer faces GLP-1 competition and patent expirations; General Mills faces inflation-driven margin pressure and evolving consumer demand; UPS outlines a turnaround with a 2H2026 inflection point after a post-pandemic volume normalization. The dividend yields are enticing, but a rebound depends on multiple catalysts aligning in a soft macro environment. If earnings momentum stalls or costs stay elevated, the 'rebound' could disappoint, and multiple compression may outpace any yield advantage.
Strongest counterpoint: even if catalysts delay, these stocks' cash flow and defensiveness could still support a multi-year base. A risk-on rally could re-rate them quickly once inflation cools and earnings surprise to the upside.
"The valuation of these high-yield stocks is driven more by interest rate expectations than by the specific operational headwinds cited by the panel."
Claude, you’re missing the macro tailwind: interest rate sensitivity. While you focus on structural headwinds, these companies are essentially bond proxies. If the Fed pivots to a sustained easing cycle, the discount rate compression alone will force a re-rating of these high-yielders, regardless of their operational sluggishness. We are ignoring the 'duration' risk of these equities. If rates stay at 5%, they are value traps; if they drop to 3%, they are defensive winners.
"Interest rate easing won't prevent dividend cuts if free cash flow coverage ratios deteriorate below 1.1x due to structural headwinds."
Gemini, your rate-sensitivity thesis overlooks payout fragility: PFE's FCF covered dividends 1.3x in 2023 but trends toward 1.0x with patent losses; GIS at 1.4x faces volume erosion; UPS post-Teamsters at ~1.2x. Easing boosts relative yields, but if ratios slip below 1.1x amid high rates lingering into 2025, cuts trigger regardless of Fed pivots—micro trumps macro here.
"Rate compression alone can't save these if FCF coverage deteriorates faster than rates fall."
Grok's payout coverage math is tighter than Gemini's rate thesis admits, but both miss timing. PFE/GIS/UPS don't need rates to hit 3%—they need *earnings* stabilization first. If FCF ratios compress to 1.0x while rates stay elevated, a rate cut becomes irrelevant; the dividend gets cut anyway. Gemini's duration play assumes operational stability as a given. It isn't. Rate easing is a necessary condition, not sufficient.
"Rate cuts alone won't rescue Pfizer, General Mills, and UPS unless earnings stabilize and payout risk is addressed; macro relief is not a substitute for secular headwinds."
Gemini, rate-paths are not a free pass here. Even if 5% yields compress toward 3%, the equity multiple needs real earnings stabilization for a meaningful rerate—these three face secular headwinds that can erode FCF and payout safety long before macro rates move. The bigger risk is payout fragility and structural demand shifts, which can keep the stock at asset-like yields without a durable re-rate if liquidity conditions stay tight.
The panel consensus is overwhelmingly bearish on PFE, GIS, and UPS, citing structural headwinds, patent cliffs, and unsustainable dividend yields. They agree that these companies are not value investments but potential value traps.
Potential re-rating due to interest rate sensitivity (Gemini's stance)
Dividend cuts due to unsustainable payout ratios and earnings disappointments